Scientists test new pill to boost power of leukemia chemotherapy
NCT ID NCT04190550
Summary
This early-stage study is testing a new oral drug called navtemadlin (KRT-232) in combination with standard chemotherapy for adults newly diagnosed with a fast-growing blood cancer called acute myeloid leukemia (AML). The main goals are to find the safest and most effective dose of the new combination and to understand its side effects. Researchers hope adding navtemadlin, which targets a specific protein in cancer cells, will help control the leukemia better than chemotherapy alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
Conditions
Explore the condition pages connected to this study.